Real-world evidence shows Pluvicto matches pivotal trial benefits in PSMA-positive mCRPC, with longer PFS after one ARPI and delayed chemotherapy.

A new study using serial liquid biopsies to track how metastatic prostate cancer evolves under treatment pressure showed that androgen receptor (AR) alterations consistently emerged and were linked to ...

Overall these findings indicate that adding cabazitaxel to long-term androgen deprivation therapy and radiotherapy did not improve long-term outcomes and increased toxicity in men with high-risk ...

Androgens can drive prostate cancer growth, thus providing the rationale for using deprivation of androgens as a first line of treatment for prostate cancer. Unfortunately, prostate cancer cells adapt ...

Longitudinal PRO modeling, rather than time-to-worsening censoring, indicated maintained HRQOL and pain outcomes with ...

The androgen receptor is the primary driver of the initiation and growth of prostate cancer, the second-leading cause of death in men. Looking to have a better understanding of how the androgen ...

A poorly characterized protein, historically thought to be a chaperone or enzyme, may actually be a key player in prostate cancer. In a systematic CRISPR screen, scientists from Arc Institute, UCSF, ...

Researchers from the University of Otago—Ōtākou Whakaihu Waka have created a world-first epigenetic tool that has implications for medicine, sports, and agriculture. In a study published in the ...

There are more than 2 million prostate cancer survivors in the United States. Primary therapy with surgery or radiation results in permanent changes in sexual function. More than half of these men are ...

The androgen clock is rewriting the science of aging, offering a precise way to measure hormone exposure and its profound effects on health, longevity, and biology. Study: The androgen clock is an ...